Skip to Main Content

Practice Impact Extra

Dr. Bernard Monteleone, former Head of Cardiology at St. Francis Hospital in New York, gives an informed analysis of highly-anticipated trials and whether or not their findings could impact clinical practice guidelines and reduce the risk of cardiovascular disease.

You may follow this podcast on Apple Podcasts, Spotify, Stitcher, iHeartRadio, or copy the RSS Feed and paste it into your podcast application: https://feeds.soundcloud.com/users/soundcloud:users:707224624/sounds.rss

Episode 45: COVID and Athletes
By Bernard Monteleone, MD
2:54
Episode 49: Beta Blocker Therapy
By Bernard Monteleone, MD
5:01
Episode 35: COVID and Athletes
By Bernard Monteleone, MD
4:12
Episode 36: Reality Trial
By Bernard Monteleone, MD
3:43
Episode 37: EMPEROR: Reduced Trial
By Bernard Monteleone, MD
3:30
Episode 38: PARALLAX Study
By Bernard Monteleone, MD
3:25
Episode 39: EVAPORATE Trial Follow-Up
By Bernard Monteleone, MD
2:56
Episode 40: EAST: AFNET
By Bernard Monteleone, MD
2:52
Episode 22: Prevention after ESUS
By Bernard Monteleone, MD
4:55
Episode 23: Anticoagulants and Bone Health
By Bernard Monteleone, MD
3:53
Episode 25: FOURIER and Evolocumab
By Bernard Monteleone, MD
3:46
Episode 26: Coconut Oil and CVD Risk
By Bernard Monteleone, MD
3:48
Episode 27: Cardiac Function Post Covid 19
By Bernard Monteleone, MD
3:13
Episode 28: Bempedoic Acid and Diabetes
By Bernard Monteleone, MD
3:34
Episode 29: COAPT Trial
By Bernard Monteleone, MD
5:20
Episode 19: COVID AND Anticoagulants
By Bernard Monteleone, MD
3:15
Episode 20: ACE and COVID: Four Studies
By Bernard Monteleone, MD
5:02
Episode 06: The ODYSSEY Trial
By Bernard Monteleone, MD
4:30
Episode 04: DAPA2 Trial and the Elderly
By Monteleone Bernard, MD
3:05
Back to Top